Drug Trial Radar · NCT00030966
Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Jun 18, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,200
Actual
Start
Jan 2002
Primary completion
Apr 2005
Study completion Dec 2005
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- Collaborators
- Elan Pharmaceuticals
- First posted
- Feb 18, 2002
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if natalizumab in combination with AVONEX is safe and effective in delaying progression of individuals diagnosed with relapsing remitting Multiple Sclerosis (MS).
Conditions
- Multiple Sclerosis, Relapsing-Remitting
Interventions
NatalizumabDrug
Natalizumab, 300 mg, monthly IV infusion for up to 116 weeks.
PlaceboDrug
Placebo monthly infusion for up to 116 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary objectives of this study are to determine if natalizumab is effective in reducing the rate of clinical relapse at 1 year and in slowing the progression of disability at 2 years as measured by EDSS.Time frame: 1 year and 2 years
Locations
88 sites in 7 countries. Site status is shown where the registry gives one.
University of Alabama-Birmingham, Department of Neurology
Birmingham, Alabama
Phoenix Neurological Associates, Ltd.
Phoenix, Arizona
University of Arkansas For Medical Sciences
Little Rock, Arkansas
University of California - Irvine
Irvine, California
USC MS Comprehensive Care Center
Los Angeles, California
Kaiser-Permanente Medical Center
Redwood City, California
MS Center at UCSF
San Francisco, California
Healthsouth Rehabilitation Hospital
Colorado Springs, Colorado
University of Colorado MS Center
Denver, Colorado
Griffin Hospital
Derby, Connecticut
Georgetown Univesity Hospital, Research Pharmacy
Washington D.C., District of Columbia
George Washington University MS Center
Washington D.C., District of Columbia
North Ridge NeuroScience Center
Fort Lauderdale, Florida
Maitland Neurology
Maitland, Florida
University of Miami, Department of Neurology
Miami, Florida
The Multiple Sclerosis Center of Atlanta
Atlanta, Georgia
Marietta Neurological Associates
Marietta, Georgia
Northwestern University, Department of Neurology
Chicago, Illinois
Rush-Presbyterian St. Luke's Medical Center
Chicago, Illinois
Alexian Brothers Center for Clinical Research
Elk Grove Village, Illinois
Loyola Medical Center
Maywood, Illinois
Consultants in Neurology Northbrook
Northbrook, Illinois
Springfield Clinic Neuroscience Institute
Springfield, Illinois
Indiana University Medical Center
Indianapolis, Indiana
Mercy Hospital Outpatient Pharmacy
Des Moines, Iowa
LSU Neurolgoy Clinic in New Orleans
New Orleans, Louisiana
Maine Neurology
Scarborough, Maine
University of Maryland Hospital, Department of Neurology
Baltimore, Maryland
Brigham and Women's Hospital
Boston, Massachusetts
University of Massachusetts Memorial Medical Center
Worcester, Massachusetts
Henry Ford Hospital
Detroit, Michigan
Michigan State University MS Clinic
East Lansing, Michigan
Michigan Institute for Neurological Disorders
Farmington Hills, Michigan
Noran Neurological Clinic
Minneapolis, Minnesota
University of Mississippi Medical Center
Jackson, Mississippi
St. John's Mercy Medical Center
St Louis, Missouri
Bernard W. Gimbel MS Center
Teaneck, New Jersey
Upstate Clinical Research, LLC
Albany, New York
Albany Medical Center
Albany, New York
Maimonides Medical Center, Division of Neurology
Brooklyn, New York
Showing 40 of 88 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.